Overview

Combination Chemotherapy in Treating Women With Breast Cancer

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
Female
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether doxorubicin plus docetaxel is more effective than doxorubicin plus cyclophosphamide for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of doxorubicin in combination with either docetaxel or cyclophosphamide in treating women who have previously untreated, advanced, or inflammatory breast cancer.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Scottish Cancer Therapy Network
Treatments:
Cyclophosphamide
Docetaxel
Doxorubicin
Liposomal doxorubicin
Tamoxifen
Criteria
DISEASE CHARACTERISTICS: Histologically proven previously untreated locally advanced or
inflammatory breast cancer Potentially operable disease Tumor at least 3 cm in diameter No
metastases Hormone receptor status: Not specified

PATIENT CHARACTERISTICS: Age: 18 to 60 Sex: Female Menopausal status: Not specified
Performance status: ECOG 0-1 Life expectancy: Not specified Hematopoietic: Absolute
neutrophil count greater than 1500/mm3 Platelet count greater than 100,000/mm3 Hemoglobin
greater than 9 g/dL Hepatic: PT and aPTT normal Bilirubin normal (except in patients with
benign congenital hyperbilirubinemia) AST/ALT no greater than 1.5 times upper limit of
normal (ULN) Alkaline phosphatase no greater than 1.5 times ULN No active hepatitis B or C
Liver biopsy normal (if positive serology for hepatitis B or C) Renal: Creatinine normal
Cardiovascular: Adequate cardiac function No active cardiac disease Other: Not pregnant
Fertile patients must use effective contraception No other serious medical or psychiatric
disease No prior or concurrent malignancy except basal cell skin cancer or carcinoma in
situ of the cervix HIV negative

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified
Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: See Disease
Characteristics Other: No prior therapy for breast cancer